MD Anderson, C-Biomex sign collaborative research agreement to co-develop CBT-001 radioligand therapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MD Anderson Cancer Center and C-Biomex Ltd. have formed a strategic research collaboration agreement to co-develop CBT-001, a radioligand targeting the CA9 cancer biomarker.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login